Xponance Inc. Buys Shares of 11,310 Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Xponance Inc. purchased a new position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 11,310 shares of the biotechnology company’s stock, valued at approximately $50,000.

Several other institutional investors have also made changes to their positions in the stock. Journey Strategic Wealth LLC acquired a new position in Ironwood Pharmaceuticals in the 4th quarter valued at approximately $45,000. Catalyst Funds Management Pty Ltd acquired a new position in shares of Ironwood Pharmaceuticals in the fourth quarter worth $47,000. SG Americas Securities LLC acquired a new position in shares of Ironwood Pharmaceuticals in the fourth quarter worth $53,000. CIBC Asset Management Inc purchased a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth $53,000. Finally, Wolverine Trading LLC acquired a new stake in Ironwood Pharmaceuticals during the third quarter valued at $51,000.

Insider Activity at Ironwood Pharmaceuticals

In related news, CMO Michael Shetzline sold 41,269 shares of the business’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $72,633.44. Following the completion of the transaction, the chief marketing officer now owns 554,007 shares of the company’s stock, valued at approximately $975,052.32. The trade was a 6.93 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas A. Mccourt sold 139,064 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $244,752.64. Following the completion of the sale, the chief executive officer now directly owns 1,160,634 shares in the company, valued at $2,042,715.84. This trade represents a 10.70 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 192,381 shares of company stock worth $338,591. 12.90% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have weighed in on IRWD. Craig Hallum dropped their target price on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. StockNews.com upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. Finally, JMP Securities cut their price objective on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.60.

Ironwood Pharmaceuticals Stock Performance

IRWD opened at $1.41 on Friday. The company has a market cap of $225.64 million, a PE ratio of -47.00 and a beta of 0.37. The stock has a 50-day moving average of $2.04 and a 200-day moving average of $3.38. Ironwood Pharmaceuticals, Inc. has a 52-week low of $1.34 and a 52-week high of $8.64.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The company had revenue of $90.55 million for the quarter, compared to the consensus estimate of $93.85 million. On average, research analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.